Science Explorer Back to mapMap
Discussion
Topic · Oncology

Cancer-related Molecular Pathways

Cancer-related Molecular Pathways is a research topic within Oncology. Science Explorer counts 48k research works in it since 1950. 10.1% of them reached the world's top 10% most cited for their field and year.

This cluster of papers focuses on the p53 signaling network, exploring its role in cell cycle regulation, tumor suppression, cancer therapy, apoptosis, and the impact of mutations. The papers cover various aspects of p53-MDM2 interaction, cyclin-dependent kinases, and the intricate mechanisms of p53 regulation in the context of cancer research.

  • p53
  • cell cycle
  • MDM2
  • tumor suppression
  • cancer therapy
  • apoptosis
  • CDKs
  • mutation
  • regulation
  • oncogene
Research works
48k
fractional, since 1950
In the world top 10%
4.8k
per year above
Top-10% rate
10.1%
share of its works in the world top 10%
Growth, 2018-21 → 2022-25
-14%
the tick is no change
Largest producer
China
34% of the 10 largest, 2022-now
Cancer-related Molecular Pathways

This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.

Which countries lead Cancer-related Molecular Pathways research?

By volume, China and the United States publish the most (1.4k and 1.3k works in 2022-now).

By volume, 2022-now

  1. 1 China 1.4k works
  2. 2 United States 1.3k works
  3. 3 India 338 works
  4. 4 Japan 225 works
  5. 5 Germany 172 works
  6. 6 Italy 165 works
  7. 7 United Kingdom 164 works
  8. 8 South Korea 147 works
  9. 9 Canada 110 works
  10. 10 France 99 works

How concentrated that is

The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.

China: 34.0%United States: 32.2%India: 8.1%Japan: 5.4%6 others listed: 20.4%34%largest
China1,424 · 34.0%United States1,350 · 32.2%India338 · 8.1%Japan225 · 5.4%6 others listed857 · 20.4%

Shares of the rows listed above, not of the whole node.

Which institutions lead Cancer-related Molecular Pathways research?

By volume in 2022-now, Harvard University publishes the most Cancer-related Molecular Pathways research, followed by The University of Texas MD Anderson Cancer Center and National Institutes of Health.

By volume, 2022-now

  1. 1 Harvard UniversityUnited States 66 works
  2. 2 The University of Texas MD Anderson Cancer CenterUnited States 56 works
  3. 3 National Institutes of HealthUnited States 41 works
  4. 4 Shanghai Jiao Tong UniversityChina 36 works
  5. 5 Sun Yat-sen UniversityChina 35 works
  6. 6 Zhejiang UniversityChina 33 works
  7. 7 University of North Carolina at Chapel HillUnited States 33 works
  8. 8 Chinese Academy of SciencesChina 30 works
  9. 9 Central South UniversityChina 26 works
  10. 10 Sichuan UniversityChina 26 works

Who are the leading researchers in Cancer-related Molecular Pathways?

The most-cited researchers publishing on Cancer-related Molecular Pathways include Eric S. Lander, George Davey Smith and Walter Churchill Willett.

  1. 1 Eric S. Lander United States 524k citations
  2. 2 George Davey Smith United Kingdom 435k citations
  3. 3 Walter Churchill Willett United States 411k citations
  4. 4 Stacey L. Gabriel United States 402k citations
  5. 5 Peer Bork Germany 396k citations
  6. 6 Guido Kroemer France 386k citations
  7. 7 Bert Vogelstein United States 373k citations
  8. 8 Gad A. Getz United States 364k citations
  9. 9 Jost Bruno Jonas Germany 350k citations
  10. 10 Elaine R. Mardis United States 346k citations

Ranked by citations received across their whole record, among researchers with at least three works on this topic.

What are the most cited papers in Cancer-related Molecular Pathways?

The most cited paper in Cancer-related Molecular Pathways is "Hallmarks of Cancer: The Next Generation" (Douglas Hanahan, Robert A. Weinberg, 2011), with 67,836 citations. Next come "The Hallmarks of Cancer" (28,893) and "Stem cells, cancer, and cancer stem cells" (9,797).

Most cited papers
#PaperReleasedCitations
1 Hallmarks of Cancer: The Next Generation Douglas Hanahan, Robert A. Weinberg · Cell Open access Mar 2011 67,836
2 The Hallmarks of Cancer Douglas Hanahan, Robert A. Weinberg · Cell Open access 2000 28,893
3 Stem cells, cancer, and cancer stem cells Tannishtha Reya, Sean J. Morrison, Michael F. Clarke et al. · Nature Open access Nov 2001 9,797
4 THE UBIQUITIN SYSTEM Avram Hershko, Aaron J. Ciechanover · Annual Review of Biochemistry Review Jun 1998 8,852
5 WAF1, a potential mediator of p53 tumor suppression Wafik S. El‐Deiry, Takashi Tokino, Victor E. Velculescu et al. · Cell Open access Nov 1993 8,417
All 100 most cited papers, with filters and sorting

Where is Cancer-related Molecular Pathways research done?

The largest centres of Cancer-related Molecular Pathways research in 2022-now are Beijing (China), Shanghai (China), Houston (United States) and New York (United States). Among places with at least 20 works in it, it is an unusually large share of all research in Houston, Tampa and Bethesda.

Largest cities, 2022-now

  1. 1 BeijingChina 131 works
  2. 2 ShanghaiChina 120 works
  3. 3 HoustonUnited States 86 works
  4. 4 New YorkUnited States 83 works
  5. 5 GuangzhouChina 82 works
  6. 6 SeoulSouth Korea 73 works
  7. 7 HangzhouChina 68 works
  8. 8 NanjingChina 63 works
  9. 9 WuhanChina 57 works
  10. 10 BostonUnited States 56 works

Where it is the local speciality

  1. HoustonUS · 86.1 works6.6×
  2. TampaUS · 21.7 works5.9×
  3. BethesdaUS · 33.9 works5.3×
← less than its size predicts1×more →

Location quotient: how much more of its research is in Cancer-related Molecular Pathways than the world average.

See Cancer-related Molecular Pathways on the map

Where is the best place to study Cancer-related Molecular Pathways?

Among universities, judged by research, Harvard University, Columbia University and China Pharmaceutical University score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.

0%10%20%30%mean 17.65%fractional works in this field (log) →share of work in the world top 10% →Harvard UniversityColumbia UniversityChina Pharmaceutical…University of Toronto
above the meannear itbelow it

One dot per university in the first ten of the table below, at the default weights. The upper left is the interesting corner: small places doing unusually strong work.

Excellenceshare of its work in the world top 10%, 2022-now and all time averaged
40%
Specialisationhow much of its work is in this field, counted up to 10× the world share
10%
Sizeits output in this field, on a log scale
30%
Growthoutput growth, counted from -20% to +20%
10%
Internationalshare of its work with a co-author abroad
10%
Each slider sets a weight; the share it gets of the score is beside it.
#UniversityScoreTop 10%SpecialisationWorksGrowth
1Harvard UniversityUnited States 84.525.9%4.4×66 -9.4%
2Columbia UniversityUnited States 62.325.8%2.8×15 +31.3%
3China Pharmaceutical UniversityChina 53.715.8%17.5×18 +24.5%
4University of TorontoCanada 48.211.6%2.7×26 -10.6%
5University of South ChinaChina 46.625.5%6.3×8 +127.8%
6Zhejiang UniversityChina 45.715.8%2.6×33 -12.6%
7Brown UniversityUnited States 44.111.7%5.8×13 +97.0%
8Sichuan UniversityChina 44.017.6%2.5×26 -2.4%
9University of California, San FranciscoUnited States 43.812.7%4.5×15 -26.5%
10University of PennsylvaniaUnited States 43.214.1%3.5×18 -4.4%

Universities only. The score blends excellence (40%), size (30%), specialisation (10%), growth (10%), international reach (10%), 2022-now; growth compares 2018-21 with 2022-25 and counts up to +20%, since a jump from a small base is mostly noise.

Every institution in Cancer-related Molecular Pathways, country by country

Is Cancer-related Molecular Pathways research growing?

Output in 2022-2025 was 14% lower than in 2018-2021, peaking in 2011.

still counting19801990200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Cancer-related Molecular Pathways as a percentage of every work published that year, 0.021% in 2024.

still counting0.050%0.10%0.15%Cancer-related Molecular Pathways0.021% in 202519801990200020102020

Fractional works of Cancer-related Molecular Pathways over all fractional works that year. How the balance of science has shifted.

How much of it reaches the world top 10%

Year by year.

still counting5%10%15%Cancer-related Molecular Pathways10.3% in 2025200020102020

Of each year's works in it, the share that reached the world's 10% most cited for their field and year. A field is the world for its own topics, so there is no other line to hold it against.

Which topics inside it are moving

Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.

Discussion

Ask a question or share a note about Cancer-related Molecular Pathways. Posts are plain text and can be reported.